IMRA - Imara reports interim data from mid-stage tovinontrine trial in beta-thalassemia

Imara (NASDAQ:IMRA) announces data from a pre-specified interim analysis from its Forte Phase 2b clinical trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia. Shares advance 4.5% premarket. “We are encouraged by the positive trend for transfusion burden reduction at the higher dose of tovinontrine," said Rahul Ballal, Ph.D., President and CEO. Interim data continue to demonstrate a favorable safety and tolerability profile at doses of tovinontrine up to 400 mg once daily. Tovinontrine was well-tolerated, with the most frequent adverse events being nausea, headache and dizziness. Four (9.3%) subjects discontinued due to adverse events considered at least possibly related to study drug. The company looks forward to a key efficacy analysis, which is expected to occur in Q1 2022, with more subjects treated through 24 weeks. In addition, Imara (IMRA) continues to advance enrollment in the non-transfusion-dependent cohort of the trial and expect initial data in H1 2022.

For further details see:

Imara reports interim data from mid-stage tovinontrine trial in beta-thalassemia